JP2009509964A - インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途 - Google Patents
インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途 Download PDFInfo
- Publication number
- JP2009509964A JP2009509964A JP2008532459A JP2008532459A JP2009509964A JP 2009509964 A JP2009509964 A JP 2009509964A JP 2008532459 A JP2008532459 A JP 2008532459A JP 2008532459 A JP2008532459 A JP 2008532459A JP 2009509964 A JP2009509964 A JP 2009509964A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carbon atoms
- azabicyclo
- oct
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title abstract description 11
- 238000004519 manufacturing process Methods 0.000 title description 6
- 150000008316 benzisoxazoles Chemical class 0.000 title description 2
- YJMPFOXUBAJFFA-UHFFFAOYSA-N [1,2]thiazolo[4,3-b]pyridine Chemical class C1=CC=NC2=CSN=C21 YJMPFOXUBAJFFA-UHFFFAOYSA-N 0.000 title 1
- 150000002473 indoazoles Chemical class 0.000 title 1
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 344
- 238000000034 method Methods 0.000 claims abstract description 167
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims abstract description 60
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 230000004913 activation Effects 0.000 claims abstract description 9
- 101150095499 Nach gene Proteins 0.000 claims abstract description 4
- 230000007488 abnormal function Effects 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 832
- 125000000217 alkyl group Chemical group 0.000 claims description 807
- -1 carboxymethyl -O Chemical class 0.000 claims description 475
- 229910052799 carbon Inorganic materials 0.000 claims description 120
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 117
- 125000003545 alkoxy group Chemical group 0.000 claims description 115
- 125000003342 alkenyl group Chemical group 0.000 claims description 114
- 125000000304 alkynyl group Chemical group 0.000 claims description 114
- 150000003839 salts Chemical class 0.000 claims description 103
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 95
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 91
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 86
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 80
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 79
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 64
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 60
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 57
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 56
- 150000001350 alkyl halides Chemical class 0.000 claims description 56
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 56
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 55
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 229920006395 saturated elastomer Polymers 0.000 claims description 51
- 239000012453 solvate Substances 0.000 claims description 48
- 229910052801 chlorine Inorganic materials 0.000 claims description 45
- 229910052731 fluorine Inorganic materials 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 43
- 229910052760 oxygen Inorganic materials 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 229910052794 bromium Inorganic materials 0.000 claims description 40
- 150000001349 alkyl fluorides Chemical class 0.000 claims description 39
- 229910052740 iodine Inorganic materials 0.000 claims description 39
- 125000006413 ring segment Chemical group 0.000 claims description 38
- 229920001577 copolymer Chemical group 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 229910052757 nitrogen Inorganic materials 0.000 claims description 37
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 37
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- 150000001204 N-oxides Chemical class 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 239000002585 base Substances 0.000 claims description 26
- 239000012458 free base Substances 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000004414 alkyl thio group Chemical group 0.000 claims description 25
- 241000282414 Homo sapiens Species 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 21
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 206010012289 Dementia Diseases 0.000 claims description 20
- 208000010877 cognitive disease Diseases 0.000 claims description 19
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 19
- 206010027175 memory impairment Diseases 0.000 claims description 19
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000004043 oxo group Chemical group O=* 0.000 claims description 17
- 208000000044 Amnesia Diseases 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 208000028698 Cognitive impairment Diseases 0.000 claims description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 11
- 208000026139 Memory disease Diseases 0.000 claims description 11
- 125000004423 acyloxy group Chemical group 0.000 claims description 11
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 230000006984 memory degeneration Effects 0.000 claims description 11
- 208000023060 memory loss Diseases 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 9
- 230000004064 dysfunction Effects 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 9
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 8
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 229910052786 argon Inorganic materials 0.000 claims description 7
- 125000005110 aryl thio group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 230000015654 memory Effects 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 claims description 7
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 6
- 201000004810 Vascular dementia Diseases 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 230000001713 cholinergic effect Effects 0.000 claims description 6
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 6
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 6
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- LLSRLLPHUVVLQJ-UHFFFAOYSA-N 1-cycloheptyldiazepane Chemical group C1CCCCCC1N1NCCCCC1 LLSRLLPHUVVLQJ-UHFFFAOYSA-N 0.000 claims description 5
- GGTBELZDHKHESR-UHFFFAOYSA-N 2-cycloheptyloxazepane Chemical group C1CCCCCC1N1OCCCCC1 GGTBELZDHKHESR-UHFFFAOYSA-N 0.000 claims description 5
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 230000006735 deficit Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- CHHKUKIZVHLZHF-WMZOPIPTSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 CHHKUKIZVHLZHF-WMZOPIPTSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 206010057852 Nicotine dependence Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 4
- LJEXBQWZLZFSSN-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-methoxyindazole-3-carboxamide Chemical compound C12=CC=C(OC)C=C2N(CC)N=C1C(=O)N[C@@H]1C(CC2)CCN2C1 LJEXBQWZLZFSSN-HNNXBMFYSA-N 0.000 claims description 4
- KPKFCXSWRVNEBQ-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-(cyclopropylmethyl)-6-(1,3-oxazol-2-yl)indazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=C(C=C11)C=2OC=CN=2)=NN1CC1CC1 KPKFCXSWRVNEBQ-GOSISDBHSA-N 0.000 claims description 4
- VQDFGMVDXFKJGX-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-(difluoromethyl)-6-methoxyindazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NN(C(F)F)C2=CC(OC)=CC=C21 VQDFGMVDXFKJGX-CYBMUJFWSA-N 0.000 claims description 4
- SMJVOFILIBVERT-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-cyclopropyl-6-(propylcarbamoylamino)indazole-3-carboxamide Chemical compound C12=CC(NC(=O)NCCC)=CC=C2C(C(=O)N[C@H]2C3CCN(CC3)C2)=NN1C1CC1 SMJVOFILIBVERT-GOSISDBHSA-N 0.000 claims description 4
- LJEXBQWZLZFSSN-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-methoxyindazole-3-carboxamide Chemical compound C12=CC=C(OC)C=C2N(CC)N=C1C(=O)N[C@H]1C(CC2)CCN2C1 LJEXBQWZLZFSSN-OAHLLOKOSA-N 0.000 claims description 4
- AOPGWWFRFLXWRH-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-n-methyl-6-(1,3-oxazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(CC)N=C(C(=O)N(C)[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 AOPGWWFRFLXWRH-GOSISDBHSA-N 0.000 claims description 4
- NBLLSKMFNOYWGA-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-(difluoromethoxy)-n-methyl-1h-indazole-3-carboxamide Chemical compound C1=C(OC(F)F)C=C2C(C(=O)N([C@H]3C4CCN(CC4)C3)C)=NNC2=C1 NBLLSKMFNOYWGA-CQSZACIVSA-N 0.000 claims description 4
- CDIIRPQKBBSHHC-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-methoxy-n-methyl-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1N(C)C(=O)C1=NNC2=CC=C(OC)C=C21 CDIIRPQKBBSHHC-OAHLLOKOSA-N 0.000 claims description 4
- RDSODELYJDFMBF-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-5-(oxan-4-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=C2)=NNC1=CC=C2C1CCOCC1 RDSODELYJDFMBF-LJQANCHMSA-N 0.000 claims description 4
- VHMKMIXTXOLLSO-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(1,3-oxazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CO1 VHMKMIXTXOLLSO-MRXNPFEDSA-N 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 230000007135 neurotoxicity Effects 0.000 claims description 4
- 231100000228 neurotoxicity Toxicity 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 125000006308 propyl amino group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 208000028683 bipolar I disease Diseases 0.000 claims description 3
- 230000007278 cognition impairment Effects 0.000 claims description 3
- 230000003492 excitotoxic effect Effects 0.000 claims description 3
- 231100000063 excitotoxicity Toxicity 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000003551 muscarinic effect Effects 0.000 claims description 3
- YIPLPZONCABMSW-QRTARXTBSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 YIPLPZONCABMSW-QRTARXTBSA-N 0.000 claims description 3
- MQHHLXJJSOOTSK-ZBFHGGJFSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-ZBFHGGJFSA-N 0.000 claims description 3
- JRLOWLLNQWPBTN-IBYPIGCZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methoxymethyl)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(COC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 JRLOWLLNQWPBTN-IBYPIGCZSA-N 0.000 claims description 3
- OFFFQICGZLVGEA-JRZJBTRGSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(NC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 OFFFQICGZLVGEA-JRZJBTRGSA-N 0.000 claims description 3
- KWZVHFOFVCRKOY-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(OC)=CC=C21 KWZVHFOFVCRKOY-ZDUSSCGKSA-N 0.000 claims description 3
- PIDKUZOOEPTSPI-RDJZCZTQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@@H]1C(CC2)CCN2C1 PIDKUZOOEPTSPI-RDJZCZTQSA-N 0.000 claims description 3
- SNBVUKVTZTVDTO-WUJWULDRSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1F SNBVUKVTZTVDTO-WUJWULDRSA-N 0.000 claims description 3
- ZGGYIVUEFFUZRX-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrazolo[3,4-c]pyridine-3-carboxamide Chemical compound N1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 ZGGYIVUEFFUZRX-GFCCVEGCSA-N 0.000 claims description 3
- MRWSLRJLSYNXEP-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,3-oxazol-2-yl)-1-propylindazole-3-carboxamide Chemical compound C1=C2N(CCC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 MRWSLRJLSYNXEP-QGZVFWFLSA-N 0.000 claims description 3
- OPCOSSJANZPAQC-MRTLOADZSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2C1OC1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OPCOSSJANZPAQC-MRTLOADZSA-N 0.000 claims description 3
- AIEYPFNAZAQGDT-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methyl-1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 AIEYPFNAZAQGDT-GOSISDBHSA-N 0.000 claims description 3
- GPWNPAULGBLLEA-FAFZWHIHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3CC4CCC3CN4C)=CC=C21 GPWNPAULGBLLEA-FAFZWHIHSA-N 0.000 claims description 3
- ZYXWSPGDIGRWLF-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(5-methylpyrazol-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound CC1=CC=NN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 ZYXWSPGDIGRWLF-MRXNPFEDSA-N 0.000 claims description 3
- VNYHRDSBGYDAQL-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(cyclopropanecarbonylamino)-1-cyclopropylindazole-3-carboxamide Chemical compound C1CC1C(=O)NC(C=C12)=CC=C1C(C(=O)N[C@H]1C3CCN(CC3)C1)=NN2C1CC1 VNYHRDSBGYDAQL-GOSISDBHSA-N 0.000 claims description 3
- QANNTZCRFNSNGO-NVXWUHKLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-NVXWUHKLSA-N 0.000 claims description 3
- VJGNOXVGSIIBKG-NVXWUHKLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzoxazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(C(=NO2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 VJGNOXVGSIIBKG-NVXWUHKLSA-N 0.000 claims description 3
- CHHKUKIZVHLZHF-FUHWJXTLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 CHHKUKIZVHLZHF-FUHWJXTLSA-N 0.000 claims description 3
- MQHHLXJJSOOTSK-GOEBONIOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-GOEBONIOSA-N 0.000 claims description 3
- SALPMAXLHRQAPQ-NFOQDIRWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[1-(cyclopropanecarbonyl)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b]pyridin-6-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC12)CC1CCCN2C(=O)C1CC1 SALPMAXLHRQAPQ-NFOQDIRWSA-N 0.000 claims description 3
- YWHWECOSJZZXMH-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(cyclopropanecarbonyl)piperazin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC1)CCN1C(=O)C1CC1 YWHWECOSJZZXMH-LJQANCHMSA-N 0.000 claims description 3
- LSJTZJHCZCUIPE-BTQNPOSSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzoxazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1NC(=O)C1=NOC2=CC(OC)=CC=C21 LSJTZJHCZCUIPE-BTQNPOSSSA-N 0.000 claims description 3
- RAYAZVOIVKZYFJ-LLVKDONJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-[1,2]thiazolo[5,4-b]pyridine-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=NC(OC)=CC=C21 RAYAZVOIVKZYFJ-LLVKDONJSA-N 0.000 claims description 3
- ACWVOGYINHFSIT-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-phenyl-2h-pyrazolo[3,4-b]pyridine-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=NC=2C1=CC=CC=C1 ACWVOGYINHFSIT-QGZVFWFLSA-N 0.000 claims description 3
- OZIYFRRXGPXXDW-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-piperazin-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCNCC1 OZIYFRRXGPXXDW-MRXNPFEDSA-N 0.000 claims description 3
- NEHATUZWLDEXIQ-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-pyrrolidin-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCCC1 NEHATUZWLDEXIQ-MRXNPFEDSA-N 0.000 claims description 3
- GLTJKJAUUMPZNP-UKRRQHHQSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3r)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 GLTJKJAUUMPZNP-UKRRQHHQSA-N 0.000 claims description 3
- OPNCHKXTZMMPLE-GDBMZVCRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-GDBMZVCRSA-N 0.000 claims description 3
- XDPQUPREVRZXNO-LLVKDONJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-methoxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=C(F)C(OC)=CC=C21 XDPQUPREVRZXNO-LLVKDONJSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- BDDIUTHMWNWMRJ-UHFFFAOYSA-N octane;hydrobromide Chemical compound Br.CCCCCCCC BDDIUTHMWNWMRJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 2
- PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical group C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 claims description 2
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical group C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 claims description 2
- AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 claims description 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 102000009346 Adenosine receptors Human genes 0.000 claims description 2
- 108050000203 Adenosine receptors Proteins 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000031091 Amnestic disease Diseases 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 208000010496 Heart Arrest Diseases 0.000 claims description 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 208000010340 Sleep Deprivation Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 230000006986 amnesia Effects 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229930003827 cannabinoid Natural products 0.000 claims description 2
- 239000003557 cannabinoid Substances 0.000 claims description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- PPNSPIJCCHPEIW-WBVHZDCISA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(SN=C2C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 PPNSPIJCCHPEIW-WBVHZDCISA-N 0.000 claims description 2
- PPNSPIJCCHPEIW-RDJZCZTQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=C(SN=C2C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 PPNSPIJCCHPEIW-RDJZCZTQSA-N 0.000 claims description 2
- UFVCXVYNCMTGHK-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-methyl-4,5-dihydroimidazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN1CCN=C1C1=CC=C(C(=NN2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 UFVCXVYNCMTGHK-INIZCTEOSA-N 0.000 claims description 2
- SERHSHYNJAZWGI-RUINGEJQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound CC1CNCCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 SERHSHYNJAZWGI-RUINGEJQSA-N 0.000 claims description 2
- XNSPJZRHCSNVAR-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-oxo-3-propylimidazolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound O=C1N(CCC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 XNSPJZRHCSNVAR-KRWDZBQOSA-N 0.000 claims description 2
- AIEYPFNAZAQGDT-SFHVURJKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methyl-1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 AIEYPFNAZAQGDT-SFHVURJKSA-N 0.000 claims description 2
- IYXVKOKQRMOGQC-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 IYXVKOKQRMOGQC-KRWDZBQOSA-N 0.000 claims description 2
- IVYWDRAWLTUMFE-TVPLGVNVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3CC4CCC(C3)N4C)=CC=C21 IVYWDRAWLTUMFE-TVPLGVNVSA-N 0.000 claims description 2
- OTUHCJJOIWVIEF-CVMIBEPCSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(dimethylamino)pyrrolidin-1-yl]-1h-indazole-3-carboxamide Chemical compound C1C(N(C)C)CCN1C1=CC=C(C(=NN2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 OTUHCJJOIWVIEF-CVMIBEPCSA-N 0.000 claims description 2
- KRVDZCIJALCFCD-DAFXYXGESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-[methyl(2,2,2-trifluoroethyl)amino]pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(N(CC(F)(F)F)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 KRVDZCIJALCFCD-DAFXYXGESA-N 0.000 claims description 2
- XIYQUORHPQHVQN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-cyano-1h-indazole-3-carboxamide Chemical compound N#CC1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NNC2=C1 XIYQUORHPQHVQN-AWEZNQCLSA-N 0.000 claims description 2
- HSNPCRQDMDXYQW-ZOWNYOTGSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(OC)=CC=C21 HSNPCRQDMDXYQW-ZOWNYOTGSA-N 0.000 claims description 2
- OPNCHKXTZMMPLE-HOCLYGCPSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-HOCLYGCPSA-N 0.000 claims description 2
- XDPQUPREVRZXNO-NSHDSACASA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-methoxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=C(F)C(OC)=CC=C21 XDPQUPREVRZXNO-NSHDSACASA-N 0.000 claims description 2
- OMIAFJAGVHVDCS-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-cyclopropyl-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=C(C=C11)C=2SC=CN=2)=NN1C1CC1 OMIAFJAGVHVDCS-QGZVFWFLSA-N 0.000 claims description 2
- DLARADLKNHHUJE-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-(1,3-oxazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(CC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 DLARADLKNHHUJE-MRXNPFEDSA-N 0.000 claims description 2
- KRLDSELWMMWNML-PKLMIRHRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-(1,3-oxazol-2-yl)indazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=C2N(CC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 KRLDSELWMMWNML-PKLMIRHRSA-N 0.000 claims description 2
- IKXVBFQRYVFHDF-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-propan-2-yl-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(C(C)C)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CS1 IKXVBFQRYVFHDF-QGZVFWFLSA-N 0.000 claims description 2
- HVKLEJMKAONLIB-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-(4-methyl-1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCCN1C1=CC=C(SN=C2C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 HVKLEJMKAONLIB-GOSISDBHSA-N 0.000 claims description 2
- HCHKVJNYNKHIGB-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,3-thiazol-2-yl)-1-thiophen-3-ylindazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=C(C=C11)C=2SC=CN=2)=NN1C=1C=CSC=1 HCHKVJNYNKHIGB-GOSISDBHSA-N 0.000 claims description 2
- SERHSHYNJAZWGI-LRHAYUFXSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound CC1CNCCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 SERHSHYNJAZWGI-LRHAYUFXSA-N 0.000 claims description 2
- WGFXFRVKAYTEOV-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-ethyl-2-oxoimidazolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound O=C1N(CC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 WGFXFRVKAYTEOV-MRXNPFEDSA-N 0.000 claims description 2
- MQHHLXJJSOOTSK-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-hydroxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-BZSJEYESSA-N 0.000 claims description 2
- QANNTZCRFNSNGO-OMOCHNIRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-OMOCHNIRSA-N 0.000 claims description 2
- BIBPBHIZDKQIOZ-PVQCJRHBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methyl-2-oxopyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound O=C1C(C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 BIBPBHIZDKQIOZ-PVQCJRHBSA-N 0.000 claims description 2
- XXXHTSQDIORPMB-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methylpiperazine-1-carbonyl)-1h-indazole-3-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 XXXHTSQDIORPMB-GOSISDBHSA-N 0.000 claims description 2
- FJXJLRUWWLSMTO-IRFCIJBXSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-(cyclopropylmethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2CC1CC1 FJXJLRUWWLSMTO-IRFCIJBXSA-N 0.000 claims description 2
- DOUKNGQHWNTBGW-CMKODMSKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-cyclopropyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2C1CC1 DOUKNGQHWNTBGW-CMKODMSKSA-N 0.000 claims description 2
- DQWZCYLIBXHEIN-XYJFISCASA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(N(C[C@]3([H])C4)C)[H])=CC=C21 DQWZCYLIBXHEIN-XYJFISCASA-N 0.000 claims description 2
- VJGNOXVGSIIBKG-DOTOQJQBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzoxazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=C(C(=NO2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 VJGNOXVGSIIBKG-DOTOQJQBSA-N 0.000 claims description 2
- AFFLFHWMOOWDQB-ROPPNANJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(cyclopropylmethoxy)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(C1)CCC1OCC1CC1 AFFLFHWMOOWDQB-ROPPNANJSA-N 0.000 claims description 2
- OFFFQICGZLVGEA-FBMWCMRBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(NC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 OFFFQICGZLVGEA-FBMWCMRBSA-N 0.000 claims description 2
- KRVDZCIJALCFCD-UHUGOGIASA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-[methyl(2,2,2-trifluoroethyl)amino]pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(N(CC(F)(F)F)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 KRVDZCIJALCFCD-UHUGOGIASA-N 0.000 claims description 2
- HSNPCRQDMDXYQW-BTQNPOSSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(OC)=CC=C21 HSNPCRQDMDXYQW-BTQNPOSSSA-N 0.000 claims description 2
- GLTJKJAUUMPZNP-DZGCQCFKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](O)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 GLTJKJAUUMPZNP-DZGCQCFKSA-N 0.000 claims description 2
- GGWTWAGLQPRLGQ-UTONKHPSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-methoxy-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=C1C=CC=C2OC GGWTWAGLQPRLGQ-UTONKHPSSA-N 0.000 claims description 2
- WQLZMRXMTRRRQR-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(oxan-4-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1CCOCC1 WQLZMRXMTRRRQR-LJQANCHMSA-N 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- 210000000225 synapse Anatomy 0.000 claims description 2
- TYUVKZGQQUXSOU-UHFFFAOYSA-N [C].OF Chemical compound [C].OF TYUVKZGQQUXSOU-UHFFFAOYSA-N 0.000 claims 20
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 5
- YNUPAYMXLKKJQU-UHFFFAOYSA-N 2-amino-2-hydroxy-2-nitroacetonitrile Chemical compound N#CC(O)(N)[N+]([O-])=O YNUPAYMXLKKJQU-UHFFFAOYSA-N 0.000 claims 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 4
- 150000003857 carboxamides Chemical class 0.000 claims 3
- XHLPSFUPKCQDKE-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-propyl-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(CCC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CS1 XHLPSFUPKCQDKE-QGZVFWFLSA-N 0.000 claims 3
- YMWLIMACGUHANC-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(1,3-thiazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CS1 YMWLIMACGUHANC-MRXNPFEDSA-N 0.000 claims 3
- OEJKUAYPQOVDOO-NNBQYGFHSA-N 6-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CN2CCCC2CN1C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OEJKUAYPQOVDOO-NNBQYGFHSA-N 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- YVMOPDSEFSCIBW-SFHVURJKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(oxan-4-yloxy)-1h-indazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=C2)=NNC1=CC=C2OC1CCOCC1 YVMOPDSEFSCIBW-SFHVURJKSA-N 0.000 claims 2
- PBHKPYHGXWPPBB-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCCNCC1 PBHKPYHGXWPPBB-KRWDZBQOSA-N 0.000 claims 2
- OPCOSSJANZPAQC-OYKVQYDMSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2C1OC1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OPCOSSJANZPAQC-OYKVQYDMSA-N 0.000 claims 2
- GPWNPAULGBLLEA-TVPLGVNVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3CC4CCC3CN4C)=CC=C21 GPWNPAULGBLLEA-TVPLGVNVSA-N 0.000 claims 2
- FEDPYWYAMNIXBE-UTONKHPSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrazolo[3,4-c]pyridine-3-carboxamide;formic acid Chemical compound OC=O.N1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 FEDPYWYAMNIXBE-UTONKHPSSA-N 0.000 claims 2
- PPNSPIJCCHPEIW-NVXWUHKLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(SN=C2C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 PPNSPIJCCHPEIW-NVXWUHKLSA-N 0.000 claims 2
- UFVCXVYNCMTGHK-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-methyl-4,5-dihydroimidazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN1CCN=C1C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 UFVCXVYNCMTGHK-MRXNPFEDSA-N 0.000 claims 2
- GRUNLFXWKKKXLJ-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-oxo-3-propylimidazolidin-1-yl)-1h-indazole-3-carboxamide Chemical compound O=C1N(CCC)CCN1C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 GRUNLFXWKKKXLJ-GOSISDBHSA-N 0.000 claims 2
- JCBHEXJAZCRMNJ-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methylpyrazol-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound N1=C(C)C=CN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 JCBHEXJAZCRMNJ-MRXNPFEDSA-N 0.000 claims 2
- QANNTZCRFNSNGO-DOTOQJQBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-DOTOQJQBSA-N 0.000 claims 2
- QKJMBWFYXTZCSM-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(difluoromethoxy)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC(F)F)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QKJMBWFYXTZCSM-BZSJEYESSA-N 0.000 claims 2
- JRLOWLLNQWPBTN-XPKAQORNSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methoxymethyl)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(COC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 JRLOWLLNQWPBTN-XPKAQORNSA-N 0.000 claims 2
- SRHHXHOIKKDDOY-UHFFFAOYSA-N octane;hydroiodide Chemical compound I.CCCCCCCC SRHHXHOIKKDDOY-UHFFFAOYSA-N 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 claims 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- LXABWBMNYBJOLI-UHFFFAOYSA-N 1H-indazole-3-carbonyl isocyanate Chemical compound C(=O)=NC(=O)C1=NNC2=CC=CC=C12 LXABWBMNYBJOLI-UHFFFAOYSA-N 0.000 claims 1
- DNAZCSLXJXKFSN-VJIKYCBLSA-N 5-hydroxy-n-[(3s)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide;iodide Chemical compound [I-].C1=C(O)C=C2C(C(=O)N[C@H]3C4CC[N+](CC4)(C3)C)=NSC2=C1 DNAZCSLXJXKFSN-VJIKYCBLSA-N 0.000 claims 1
- OEJKUAYPQOVDOO-WHCXFUJUSA-N 6-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CN2CCCC2CN1C1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OEJKUAYPQOVDOO-WHCXFUJUSA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 238000002695 general anesthesia Methods 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- QANNTZCRFNSNGO-LWKPJOBUSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-LWKPJOBUSA-N 0.000 claims 1
- FJXJLRUWWLSMTO-ZJOUEHCJSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-(cyclopropylmethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2CC1CC1 FJXJLRUWWLSMTO-ZJOUEHCJSA-N 0.000 claims 1
- SALPMAXLHRQAPQ-QUENFVSXSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[1-(cyclopropanecarbonyl)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b]pyridin-6-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC12)CC1CCCN2C(=O)C1CC1 SALPMAXLHRQAPQ-QUENFVSXSA-N 0.000 claims 1
- OZIYFRRXGPXXDW-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-piperazin-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCNCC1 OZIYFRRXGPXXDW-INIZCTEOSA-N 0.000 claims 1
- OPNCHKXTZMMPLE-ZBFHGGJFSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-ZBFHGGJFSA-N 0.000 claims 1
- YLWNWPRABKNCGA-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-(difluoromethyl)-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(C(F)F)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CS1 YLWNWPRABKNCGA-CQSZACIVSA-N 0.000 claims 1
- PBHKPYHGXWPPBB-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCCNCC1 PBHKPYHGXWPPBB-QGZVFWFLSA-N 0.000 claims 1
- GJYQRQQHVVMNQQ-UNTBIKODSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-oxo-3-propylimidazolidin-1-yl)-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.O=C1N(CCC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 GJYQRQQHVVMNQQ-UNTBIKODSA-N 0.000 claims 1
- IVYWDRAWLTUMFE-FAFZWHIHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3CC4CCC(C3)N4C)=CC=C21 IVYWDRAWLTUMFE-FAFZWHIHSA-N 0.000 claims 1
- YIPLPZONCABMSW-JLJPHGGASA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 YIPLPZONCABMSW-JLJPHGGASA-N 0.000 claims 1
- YASULIPENFCLRY-CMKODMSKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2-(cyclopropanecarbonyl)-2,5-diazabicyclo[2.2.1]heptan-5-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2C(=O)C1CC1 YASULIPENFCLRY-CMKODMSKSA-N 0.000 claims 1
- GOZVSIAXGOLHQP-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(dimethylamino)piperidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 GOZVSIAXGOLHQP-LJQANCHMSA-N 0.000 claims 1
- ZCZQEVPJJXRPAQ-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-pyrrol-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1C=CC=C1 ZCZQEVPJJXRPAQ-MRXNPFEDSA-N 0.000 claims 1
- OPNCHKXTZMMPLE-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-BZSJEYESSA-N 0.000 claims 1
- OPNCHKXTZMMPLE-GOEBONIOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-GOEBONIOSA-N 0.000 claims 1
- SNBVUKVTZTVDTO-AWKYBWMHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1F SNBVUKVTZTVDTO-AWKYBWMHSA-N 0.000 claims 1
- INYJGWAMAOSZQJ-UHFFFAOYSA-N oxamide;hydrochloride Chemical compound Cl.NC(=O)C(N)=O INYJGWAMAOSZQJ-UHFFFAOYSA-N 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 27
- 239000003446 ligand Substances 0.000 abstract description 15
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract description 11
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- 239000011541 reaction mixture Substances 0.000 description 62
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- 239000002253 acid Substances 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- 239000000243 solution Substances 0.000 description 47
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 44
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 239000007787 solid Substances 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 28
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- 239000010410 layer Substances 0.000 description 23
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 22
- 235000019341 magnesium sulphate Nutrition 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 241000124008 Mammalia Species 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 19
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 18
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 235000019253 formic acid Nutrition 0.000 description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 17
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 17
- 150000007513 acids Chemical class 0.000 description 16
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 16
- 150000001408 amides Chemical class 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 14
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 14
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- UEXCJVNBTNXOEH-UHFFFAOYSA-N phenyl acethylene Natural products C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 14
- 238000001914 filtration Methods 0.000 description 13
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 9
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 9
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- AUBPMADJYNSPOA-UHFFFAOYSA-N Anabaseine Chemical compound C1CCCC(C=2C=NC=CC=2)=N1 AUBPMADJYNSPOA-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 239000004305 biphenyl Substances 0.000 description 7
- 235000010290 biphenyl Nutrition 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 125000001624 naphthyl group Chemical group 0.000 description 7
- 229960002715 nicotine Drugs 0.000 description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 238000006880 cross-coupling reaction Methods 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 150000003335 secondary amines Chemical class 0.000 description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 5
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229940044601 receptor agonist Drugs 0.000 description 5
- 239000000018 receptor agonist Substances 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 238000006193 diazotization reaction Methods 0.000 description 4
- 150000005690 diesters Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- KTORKRBAIRTBCP-UHFFFAOYSA-N 1,2-benzothiazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NSC2=C1 KTORKRBAIRTBCP-UHFFFAOYSA-N 0.000 description 3
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 3
- SZYVPWPBRABKAB-UHFFFAOYSA-N 3-bromo-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(Br)=C1 SZYVPWPBRABKAB-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000000323 Tourette Syndrome Diseases 0.000 description 3
- 208000016620 Tourette disease Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- IOCGMLSHRBHNCM-UHFFFAOYSA-N difluoromethoxy(difluoro)methane Chemical compound FC(F)OC(F)F IOCGMLSHRBHNCM-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- QHDRKFYEGYYIIK-UHFFFAOYSA-N isovaleronitrile Chemical compound CC(C)CC#N QHDRKFYEGYYIIK-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 2
- LSNTUFKHTNZVDL-UHFFFAOYSA-N 1-bromo-4-(difluoromethoxy)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(OC(F)F)=CC=C1Br LSNTUFKHTNZVDL-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- QXDAKFBVTWGQHQ-UHFFFAOYSA-N 2-nitroacetamide Chemical compound NC(=O)C[N+]([O-])=O QXDAKFBVTWGQHQ-UHFFFAOYSA-N 0.000 description 2
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 2
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 2
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 238000000297 Sandmeyer reaction Methods 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- KFDLHDGFDLHFRW-UHFFFAOYSA-N [O-][N+](Br)=O Chemical compound [O-][N+](Br)=O KFDLHDGFDLHFRW-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 230000003935 attention Effects 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- GVCAWQUJCHZRCB-UHFFFAOYSA-N ethyl 2-chloro-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Cl GVCAWQUJCHZRCB-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XIEGSJAEZIGKSA-UHFFFAOYSA-N hydron;(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1h-indole-3-carboxylate;chloride Chemical compound Cl.C1=CC=C2C(C(=O)OC3CC4CCC(C3)N4C)=CNC2=C1 XIEGSJAEZIGKSA-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- ILCQYORZHHFLNL-UHFFFAOYSA-N n-bromoaniline Chemical compound BrNC1=CC=CC=C1 ILCQYORZHHFLNL-UHFFFAOYSA-N 0.000 description 2
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000036306 sensory inhibition Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- VSLFHIMHDHPVST-UHFFFAOYSA-N tert-butyl 6-bromo-1h-indazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC(C)(C)C)=NNC2=C1 VSLFHIMHDHPVST-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical group O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- MTXSIJUGVMTTMU-JTQLQIEISA-N (S)-anabasine Chemical compound N1CCCC[C@H]1C1=CC=CN=C1 MTXSIJUGVMTTMU-JTQLQIEISA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WRGKKASJBOREMB-UHFFFAOYSA-N 1,4-dibromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1Br WRGKKASJBOREMB-UHFFFAOYSA-N 0.000 description 1
- RABOWIPUNWPBRR-UHFFFAOYSA-N 1-(2-methoxyethoxymethyl)-6-(oxan-4-yloxy)indazole-3-carboxylic acid Chemical compound C1=C2N(COCCOC)N=C(C(O)=O)C2=CC=C1OC1CCOCC1 RABOWIPUNWPBRR-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IGNPOXGBNFMJHE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-2-amine Chemical compound C1CN2C(N)CC1CC2 IGNPOXGBNFMJHE-UHFFFAOYSA-N 0.000 description 1
- YDEAOXVCOPZFJV-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane-2-carboxamide;1h-indazole Chemical compound C1=CC=C2C=NNC2=C1.C1CN2C(C(=O)N)CC1CC2 YDEAOXVCOPZFJV-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- BQLHMMQUVJCTAN-UHFFFAOYSA-N 1-chloro-3-methoxypropane Chemical compound COCCCCl BQLHMMQUVJCTAN-UHFFFAOYSA-N 0.000 description 1
- FLVFPAIGVBQGET-UHFFFAOYSA-N 1-methylpyrrolidin-3-ol Chemical compound CN1CCC(O)C1 FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 1
- DLHWKJDYXPNWAI-UHFFFAOYSA-N 2,2,2-trichloro-1-ethoxyethanol Chemical compound CCOC(O)C(Cl)(Cl)Cl DLHWKJDYXPNWAI-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- GMVGSGXEYKPCSS-UHFFFAOYSA-N 2-bromo-1-nitro-4-phenylmethoxybenzene Chemical compound C1=C(Br)C([N+](=O)[O-])=CC=C1OCC1=CC=CC=C1 GMVGSGXEYKPCSS-UHFFFAOYSA-N 0.000 description 1
- RXTRRIFWCJEMEL-UHFFFAOYSA-N 2-chloropyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1Cl RXTRRIFWCJEMEL-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UUKWKUSGGZNXGA-UHFFFAOYSA-N 3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UUKWKUSGGZNXGA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BXKYFUGAAFLYJL-BXGYHSFXSA-N 3-[(5e)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2h-pyridin-6-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 BXKYFUGAAFLYJL-BXGYHSFXSA-N 0.000 description 1
- HTKXRTUKPXEALT-UHFFFAOYSA-N 3-bromo-2h-indazole Chemical compound C1=CC=CC2=C(Br)NN=C21 HTKXRTUKPXEALT-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LTWINMJBBFVXGY-UHFFFAOYSA-N 3-methyl-[1,2]thiazolo[5,4-b]pyridine Chemical group C1=CC=C2C(C)=NSC2=N1 LTWINMJBBFVXGY-UHFFFAOYSA-N 0.000 description 1
- KXIMCEQJXLUWHI-UHFFFAOYSA-N 3-phenylmethoxy-1h-indazole Chemical class N=1NC2=CC=CC=C2C=1OCC1=CC=CC=C1 KXIMCEQJXLUWHI-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical class CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- GWMNYKPYSDQJSH-UHFFFAOYSA-N 4-amino-1h-indazole-3-carboxylic acid Chemical compound NC1=CC=CC2=C1C(C(O)=O)=NN2 GWMNYKPYSDQJSH-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- RHXWAMSYANZWMS-UHFFFAOYSA-N 4-methoxy-1h-indazole Chemical compound COC1=CC=CC2=C1C=NN2 RHXWAMSYANZWMS-UHFFFAOYSA-N 0.000 description 1
- UNCWFHMSYTUYDL-UHFFFAOYSA-N 4-methoxy-1h-indazole-3-carboxylic acid Chemical compound COC1=CC=CC2=C1C(C(O)=O)=NN2 UNCWFHMSYTUYDL-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
- REXPARGQDTXNQS-UHFFFAOYSA-N 5-(difluoromethoxy)-1h-indazole-3-carboxylic acid Chemical compound C1=C(OC(F)F)C=C2C(C(=O)O)=NNC2=C1 REXPARGQDTXNQS-UHFFFAOYSA-N 0.000 description 1
- RSERHJPLECECPR-UHFFFAOYSA-N 5-methoxy-1h-indazole-3-carboxylic acid Chemical compound COC1=CC=C2NN=C(C(O)=O)C2=C1 RSERHJPLECECPR-UHFFFAOYSA-N 0.000 description 1
- XQSDKMGSBPHGFT-UHFFFAOYSA-N 6-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole-3-carboxylic acid Chemical compound C1N(CC2)CCC2C1OC1=CC=C2C(C(=O)O)=NSC2=C1 XQSDKMGSBPHGFT-UHFFFAOYSA-N 0.000 description 1
- CGKRYEFLVDXZOX-UHFFFAOYSA-N 6-(3,6-dihydro-2h-pyran-4-yl)-1h-indazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NNC2=CC=1C1=CCOCC1 CGKRYEFLVDXZOX-UHFFFAOYSA-N 0.000 description 1
- WOTMSMCFGIWLNI-UHFFFAOYSA-N 6-(difluoromethoxy)-1h-indazole-3-carboxylic acid Chemical compound FC(F)OC1=CC=C2C(C(=O)O)=NNC2=C1 WOTMSMCFGIWLNI-UHFFFAOYSA-N 0.000 description 1
- YYJBAFCUNUMCNS-UHFFFAOYSA-N 6-(oxan-4-yl)-1h-indazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NNC2=CC=1C1CCOCC1 YYJBAFCUNUMCNS-UHFFFAOYSA-N 0.000 description 1
- FWQJCLJQWQXNTD-UHFFFAOYSA-N 6-bromo-1,2-benzothiazole-3-carboxylic acid Chemical compound BrC1=CC=C2C(C(=O)O)=NSC2=C1 FWQJCLJQWQXNTD-UHFFFAOYSA-N 0.000 description 1
- TVWVDWCIELUGGY-UHFFFAOYSA-N 6-methoxy-1,2-benzothiazole-3-carboxylic acid Chemical compound COC1=CC=C2C(C(O)=O)=NSC2=C1 TVWVDWCIELUGGY-UHFFFAOYSA-N 0.000 description 1
- ZOHKZLZEKUEPIR-UHFFFAOYSA-N 6-methoxy-1-benzothiophene-2,3-dione Chemical compound COC1=CC=C2C(=O)C(=O)SC2=C1 ZOHKZLZEKUEPIR-UHFFFAOYSA-N 0.000 description 1
- ZBTVRLZKLHRWIU-UHFFFAOYSA-N 6-phenyl-2h-pyrazolo[3,4-b]pyridine-3-carboxylic acid Chemical class C=1C=C2C(C(=O)O)=NNC2=NC=1C1=CC=CC=C1 ZBTVRLZKLHRWIU-UHFFFAOYSA-N 0.000 description 1
- JBPCEKWXGCHLSX-UHFFFAOYSA-N 6-phenylmethoxy-1h-indazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NNC2=CC=1OCC1=CC=CC=C1 JBPCEKWXGCHLSX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940122656 Alpha-7 nicotinic receptor agonist Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- CHMHHCITZUBRTF-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN2)C(=O)NC(=O)O Chemical compound C1=CC=C2C(=C1)C(=NN2)C(=O)NC(=O)O CHMHHCITZUBRTF-UHFFFAOYSA-N 0.000 description 1
- UBEZCHQCEOJPIJ-UHFFFAOYSA-K CN1C=C[N+](=C1Cl)C.CN1C=C[N+](=C1Cl)C.CN1C=C[N+](=C1Cl)C.[O-]P(=O)([O-])[O-] Chemical compound CN1C=C[N+](=C1Cl)C.CN1C=C[N+](=C1Cl)C.CN1C=C[N+](=C1Cl)C.[O-]P(=O)([O-])[O-] UBEZCHQCEOJPIJ-UHFFFAOYSA-K 0.000 description 1
- QRYFBTMNUNLJCM-UHFFFAOYSA-N COCCOCN1C2=C(C=CC(=C2)O)C(=N1)C(=O)O Chemical compound COCCOCN1C2=C(C=CC(=C2)O)C(=N1)C(=O)O QRYFBTMNUNLJCM-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 208000012184 Diffuse Brain injury Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N Nitroanisol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1 BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 241000237854 Sipunculus nudus Species 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- MNBJEUWONPHKSB-UHFFFAOYSA-N [1,2]thiazolo[5,4-b]pyridine-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NSC2=N1 MNBJEUWONPHKSB-UHFFFAOYSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- SDHUBQXHWBBSJF-UHFFFAOYSA-N [Zn][SiH3] Chemical compound [Zn][SiH3] SDHUBQXHWBBSJF-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229930014345 anabasine Natural products 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009910 autonomic response Effects 0.000 description 1
- RVSPCRWXESLLJY-UHFFFAOYSA-N azane;1h-indazole Chemical compound N.C1=CC=C2C=NNC2=C1 RVSPCRWXESLLJY-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- ZWWCURLKEXEFQT-UHFFFAOYSA-N dinitrogen pentaoxide Chemical class [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- CDEFJFAMHRYTMU-UHFFFAOYSA-N ethyl 1-(2-methoxyethoxymethyl)-6-phenylmethoxyindazole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OCC)=NN(COCCOC)C2=CC=1OCC1=CC=CC=C1 CDEFJFAMHRYTMU-UHFFFAOYSA-N 0.000 description 1
- GZKHDVAKKLTJPO-UHFFFAOYSA-N ethyl 2,2-difluoroacetate Chemical compound CCOC(=O)C(F)F GZKHDVAKKLTJPO-UHFFFAOYSA-N 0.000 description 1
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 1
- SLXRKEYPUYJUAT-UHFFFAOYSA-N ethyl 5-phenylmethoxy-1h-indazole-3-carboxylate Chemical compound C1=C2C(C(=O)OCC)=NNC2=CC=C1OCC1=CC=CC=C1 SLXRKEYPUYJUAT-UHFFFAOYSA-N 0.000 description 1
- ADEQGMXEHRCMKL-UHFFFAOYSA-N ethyl 6-bromo-1,2-benzoxazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=NOC2=C1 ADEQGMXEHRCMKL-UHFFFAOYSA-N 0.000 description 1
- KPGNWYNJQYCPHY-UHFFFAOYSA-N ethyl 6-bromo-1-(2-methoxyethoxymethyl)indazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=NN(COCCOC)C2=C1 KPGNWYNJQYCPHY-UHFFFAOYSA-N 0.000 description 1
- QJWRLFKJCOFQIS-UHFFFAOYSA-N ethyl 6-bromo-1h-indazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=NNC2=C1 QJWRLFKJCOFQIS-UHFFFAOYSA-N 0.000 description 1
- AHPUERCFANCLJO-UHFFFAOYSA-N ethyl 6-hydroxy-1-(2-methoxyethoxymethyl)indazole-3-carboxylate Chemical compound OC1=CC=C2C(C(=O)OCC)=NN(COCCOC)C2=C1 AHPUERCFANCLJO-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- UVECLJDRPFNRRQ-UHFFFAOYSA-N ethyl trifluoromethanesulfonate Chemical compound CCOS(=O)(=O)C(F)(F)F UVECLJDRPFNRRQ-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- YASULIPENFCLRY-BJLQDIEVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2-(cyclopropanecarbonyl)-2,5-diazabicyclo[2.2.1]heptan-5-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2C(=O)C1CC1 YASULIPENFCLRY-BJLQDIEVSA-N 0.000 description 1
- DQWZCYLIBXHEIN-BQFCYCMXSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(N(C[C@]3([H])C4)C)[H])=CC=C21 DQWZCYLIBXHEIN-BQFCYCMXSA-N 0.000 description 1
- YWHWECOSJZZXMH-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(cyclopropanecarbonyl)piperazin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC1)CCN1C(=O)C1CC1 YWHWECOSJZZXMH-IBGZPJMESA-N 0.000 description 1
- GOZVSIAXGOLHQP-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(dimethylamino)piperidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 GOZVSIAXGOLHQP-IBGZPJMESA-N 0.000 description 1
- DOFXBGFMCIIQDS-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-ethoxypyrrolidin-1-yl)-7-fluoro-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OCC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1F DOFXBGFMCIIQDS-BZSJEYESSA-N 0.000 description 1
- IYXVKOKQRMOGQC-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 IYXVKOKQRMOGQC-QGZVFWFLSA-N 0.000 description 1
- MKPGOIZSZGGKGK-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(difluoromethoxy)-n-methyl-1h-indazole-3-carboxamide Chemical compound FC(F)OC1=CC=C2C(C(=O)N([C@H]3C4CCN(CC4)C3)C)=NNC2=C1 MKPGOIZSZGGKGK-CQSZACIVSA-N 0.000 description 1
- CHOAZMBKIMGLCK-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-imidazol-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1C=CN=C1 CHOAZMBKIMGLCK-OAHLLOKOSA-N 0.000 description 1
- JVCZTKPKQDRXED-NYGWOBCZSA-N n-[(3s)-1-oxido-1-azoniabicyclo[2.2.2]octan-3-yl]-5-(trifluoromethoxy)-1h-indazole-3-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2C(C(=O)N[C@H]3C4CC[N+](CC4)(C3)[O-])=NNC2=C1 JVCZTKPKQDRXED-NYGWOBCZSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000014786 regulation of synaptic transmission Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71955205P | 2005-09-23 | 2005-09-23 | |
| PCT/US2006/037142 WO2007038367A1 (en) | 2005-09-23 | 2006-09-22 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009509964A true JP2009509964A (ja) | 2009-03-12 |
| JP2009509964A5 JP2009509964A5 (cg-RX-API-DMAC7.html) | 2010-01-07 |
Family
ID=37715973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532459A Pending JP2009509964A (ja) | 2005-09-23 | 2006-09-22 | インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1940833A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009509964A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080048550A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101312968A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006295397A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0617534A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2622677A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL190358A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2450003C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG165417A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007038367A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200802342B (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014061676A1 (ja) * | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2015527406A (ja) * | 2012-09-11 | 2015-09-17 | ジェンザイム・コーポレーション | グルコシルセラミド合成酵素阻害剤 |
| JP2016529248A (ja) * | 2013-08-08 | 2016-09-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピラジンアミド化合物 |
| JP2018516973A (ja) * | 2015-06-10 | 2018-06-28 | フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| NZ570524A (en) | 2006-03-28 | 2011-08-26 | High Point Pharmaceuticals Llc | Benzothiazoles having histamine H3 receptor activity |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| EA019509B1 (ru) * | 2007-11-16 | 2014-04-30 | Райджел Фармасьютикалз, Инк. | Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений |
| KR20100101171A (ko) * | 2008-02-15 | 2010-09-16 | 에프. 호프만-라 로슈 아게 | 3-알킬-피페라진 유도체 및 이의 용도 |
| DK2346833T3 (da) * | 2008-10-13 | 2013-04-29 | Hoffmann La Roche | Diazonium-fri fremgangsmåde til fremstilling af et indazolmellemprodukt i syntesen af bicyclisk 5-(trifluormethoxy)-1h-3-indazolcarboxylsyreamider |
| US8642638B2 (en) | 2008-11-19 | 2014-02-04 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| US20110172428A1 (en) | 2010-01-12 | 2011-07-14 | Shan-Ming Kuang | Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt |
| CN103025744A (zh) * | 2010-04-30 | 2013-04-03 | 百时美施贵宝公司 | 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物 |
| DK3029039T3 (en) | 2010-05-17 | 2017-12-04 | Forum Pharmaceuticals Inc | PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE |
| US8242276B2 (en) | 2010-06-30 | 2012-08-14 | Hoffmann-La Roche Inc. | Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt |
| RU2013108223A (ru) | 2010-07-26 | 2014-09-10 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных нарушений определенными агонистами рецептора никотиновой кислоты альфа-7 в сочетании с ингибиторами ацетилхолинэстеразы |
| AR086791A1 (es) * | 2011-07-01 | 2014-01-22 | Lundbeck & Co As H | Moduladores alostericos positivos del receptor de acetilcolina nicotinico |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
| CN105722830B (zh) | 2013-06-20 | 2019-06-04 | 拜耳作物科学股份公司 | 作为杀螨剂和杀昆虫剂的芳基硫醚衍生物和芳基亚砜衍生物 |
| WO2015143380A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| KR101532211B1 (ko) * | 2014-04-30 | 2015-06-30 | 세종대학교산학협력단 | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법 |
| PT3201203T (pt) | 2014-09-29 | 2021-08-09 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(1-metil-1h-pirazol-4-il)-n-((1r,5s,7s)-9-metil-3-oxa-9-azabiciclo[3.3.1]nonan-7-il)-1hindol-3-carboxamida |
| HK1253295A1 (zh) | 2015-08-12 | 2019-06-14 | Axovant Sciences Gmbh | 作为7-烟碱乙酰胆碱受体的激动剂的偕取代的氨基苯并异恶唑化合物 |
| CA3251507A1 (en) * | 2015-10-16 | 2025-05-21 | Abbvie Inc. | Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis |
| CN110709396A (zh) | 2017-04-06 | 2020-01-17 | 伊文蒂瓦公司 | Yap/taz-tead相互作用的新化合物抑制剂及其在治疗恶性间皮瘤中的用途 |
| EP3632908A1 (en) | 2018-10-02 | 2020-04-08 | Inventiva | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| MX2022009477A (es) | 2020-02-03 | 2022-08-22 | Genzyme Corp | Metodos para el tratamiento de sintomas neurologicos asociados con las enfermedades de almacenamiento lisosomico. |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| BR112023000798A2 (pt) | 2020-07-24 | 2023-02-07 | Genzyme Corp | Composições farmacêuticas compreendendo venglustat |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004016608A1 (en) * | 2002-08-14 | 2004-02-26 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
| WO2004029050A1 (en) * | 2002-09-25 | 2004-04-08 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| WO2004064836A2 (en) * | 2003-01-22 | 2004-08-05 | Pharmacia & Upjohn Company Llc | Treatment of diseases with alpha-7 nach receptor full agonists |
| JP2004534065A (ja) * | 2001-06-12 | 2004-11-11 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリジン置換二環系へテロ芳香族化合物 |
| JP2004537532A (ja) * | 2001-06-12 | 2004-12-16 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリジン置換多環式へテロアリール |
| JP2005517657A (ja) * | 2001-12-19 | 2005-06-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 二環式ｎ−アリールアミド類 |
| WO2005063767A2 (en) * | 2003-12-22 | 2005-07-14 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA93737B (en) * | 1992-02-04 | 1993-09-06 | Eisai Co Ltd | Aminobenzoic acid derivatives. |
-
2006
- 2006-09-22 JP JP2008532459A patent/JP2009509964A/ja active Pending
- 2006-09-22 WO PCT/US2006/037142 patent/WO2007038367A1/en not_active Ceased
- 2006-09-22 SG SG201006955-7A patent/SG165417A1/en unknown
- 2006-09-22 BR BRPI0617534-1A patent/BRPI0617534A2/pt not_active IP Right Cessation
- 2006-09-22 CA CA002622677A patent/CA2622677A1/en not_active Abandoned
- 2006-09-22 EP EP06815264A patent/EP1940833A1/en not_active Withdrawn
- 2006-09-22 AU AU2006295397A patent/AU2006295397A1/en not_active Abandoned
- 2006-09-22 RU RU2008115268/04A patent/RU2450003C2/ru not_active IP Right Cessation
- 2006-09-22 CN CNA2006800439794A patent/CN101312968A/zh active Pending
- 2006-09-22 KR KR1020087009574A patent/KR20080048550A/ko not_active Ceased
-
2008
- 2008-03-12 ZA ZA200802342A patent/ZA200802342B/xx unknown
- 2008-03-20 IL IL190358A patent/IL190358A0/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004534065A (ja) * | 2001-06-12 | 2004-11-11 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリジン置換二環系へテロ芳香族化合物 |
| JP2004537532A (ja) * | 2001-06-12 | 2004-12-16 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリジン置換多環式へテロアリール |
| JP2005517657A (ja) * | 2001-12-19 | 2005-06-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 二環式ｎ−アリールアミド類 |
| WO2004016608A1 (en) * | 2002-08-14 | 2004-02-26 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
| WO2004029050A1 (en) * | 2002-09-25 | 2004-04-08 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| WO2004064836A2 (en) * | 2003-01-22 | 2004-08-05 | Pharmacia & Upjohn Company Llc | Treatment of diseases with alpha-7 nach receptor full agonists |
| WO2005063767A2 (en) * | 2003-12-22 | 2005-07-14 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015527406A (ja) * | 2012-09-11 | 2015-09-17 | ジェンザイム・コーポレーション | グルコシルセラミド合成酵素阻害剤 |
| WO2014061676A1 (ja) * | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
| US9296746B2 (en) | 2012-10-16 | 2016-03-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JPWO2014061676A1 (ja) * | 2012-10-16 | 2016-09-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2016529248A (ja) * | 2013-08-08 | 2016-09-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピラジンアミド化合物 |
| JP2018516973A (ja) * | 2015-06-10 | 2018-06-28 | フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0617534A2 (pt) | 2011-07-26 |
| RU2008115268A (ru) | 2009-10-27 |
| RU2450003C2 (ru) | 2012-05-10 |
| CA2622677A1 (en) | 2007-04-05 |
| EP1940833A1 (en) | 2008-07-09 |
| IL190358A0 (en) | 2009-09-22 |
| SG165417A1 (en) | 2010-10-28 |
| ZA200802342B (en) | 2009-03-25 |
| KR20080048550A (ko) | 2008-06-02 |
| WO2007038367A1 (en) | 2007-04-05 |
| CN101312968A (zh) | 2008-11-26 |
| AU2006295397A1 (en) | 2007-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509964A (ja) | インダゾール類、ベンゾチアゾール類、ベンゾイソオキサゾール類、ピラゾロピリジン類、イソチアゾロピリジン類、およびそれらの製造と用途 | |
| US8106066B2 (en) | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | |
| JP4995075B2 (ja) | インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用 | |
| CN100484937C (zh) | 吲唑、苯并噻唑和苯并异噻唑，以及它们的制备和用途 | |
| EP1742944B1 (en) | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | |
| KR20070087674A (ko) | 니코틴 α-７ 수용체 리간드 및 이의 제조 및 용도 | |
| EP1745046B1 (en) | 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | |
| US7932248B2 (en) | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | |
| HK1122029A (en) | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | |
| CN101124226A (zh) | 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途 | |
| HK1112743A (en) | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | |
| HK1112742A (en) | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | |
| HK1083831B (en) | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090904 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090904 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120810 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120817 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120907 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120914 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130108 |